As with PNs and other clinical manifestations of NF1, increased understanding of molecular drivers in MPNST and expanded use of targeted therapies such as MEK inhibitors have paved the way for new therapeutic approaches. Here, MAP2K7 is linked to malignant peripheral nerve sheath tumor.